ES2853935T3 - Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades - Google Patents

Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades Download PDF

Info

Publication number
ES2853935T3
ES2853935T3 ES14779351T ES14779351T ES2853935T3 ES 2853935 T3 ES2853935 T3 ES 2853935T3 ES 14779351 T ES14779351 T ES 14779351T ES 14779351 T ES14779351 T ES 14779351T ES 2853935 T3 ES2853935 T3 ES 2853935T3
Authority
ES
Spain
Prior art keywords
seq
mis
cancer
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14779351T
Other languages
English (en)
Spanish (es)
Inventor
Patricia K Donahoe
Demetrios Vavvas
David Pepin
Mien Van Hoang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Massachusetts Eye and Ear
Original Assignee
General Hospital Corp
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Massachusetts Eye and Ear Infirmary filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2853935T3 publication Critical patent/ES2853935T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
ES14779351T 2013-03-12 2014-03-12 Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades Active ES2853935T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777135P 2013-03-12 2013-03-12
PCT/US2014/024010 WO2014164981A1 (en) 2013-03-12 2014-03-12 Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
ES2853935T3 true ES2853935T3 (es) 2021-09-20

Family

ID=51659030

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14779351T Active ES2853935T3 (es) 2013-03-12 2014-03-12 Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades

Country Status (14)

Country Link
US (2) US11084860B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968470B1 (cg-RX-API-DMAC7.html)
JP (4) JP6698015B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160029731A (cg-RX-API-DMAC7.html)
CN (1) CN105473154A (cg-RX-API-DMAC7.html)
AU (1) AU2014248768A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015022181A8 (cg-RX-API-DMAC7.html)
CA (1) CA2904978A1 (cg-RX-API-DMAC7.html)
DK (1) DK2968470T3 (cg-RX-API-DMAC7.html)
ES (1) ES2853935T3 (cg-RX-API-DMAC7.html)
HK (1) HK1222331A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015011846A (cg-RX-API-DMAC7.html)
PL (1) PL2968470T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014164981A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1222331A1 (zh) * 2013-03-12 2017-06-30 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用於疾病治疗的用途
US10258668B2 (en) 2013-09-20 2019-04-16 The General Hospital Corporation Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
EP4008339A1 (en) * 2013-12-11 2022-06-08 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception
MA41629A (fr) * 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US11518793B2 (en) 2016-12-14 2022-12-06 The General Hospital Corporation Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
CN107523586B (zh) * 2017-10-20 2020-03-17 广州万孚生物技术股份有限公司 免疫质粒及用于检测抗穆勒氏管激素的单抗、杂交瘤细胞及其制备方法和应用
WO2020044298A1 (en) * 2018-08-30 2020-03-05 Preglem Sa A novel use of the anti-müllerian hormone
AU2020282359A1 (en) 2019-05-31 2022-01-06 Laura DETTI Anti-Mullerian hormone receptor binding peptides
WO2021097369A2 (en) * 2019-11-13 2021-05-20 Celmatix Inc. Compositions and methods regulating folliculogenesis for the treatment of ovarian senescence
CN112251444B (zh) * 2020-10-21 2023-05-16 恺佧生物科技(上海)有限公司 一种改造的amh基因序列及利用其制备amh的方法
RU2770003C1 (ru) * 2021-04-05 2022-04-14 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к С-концевому фрагменту антимюллерова гормона
CN115554403B (zh) * 2022-08-16 2024-03-08 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用
CN120591344A (zh) * 2025-06-13 2025-09-05 广州景旸生物科技有限公司 Col3a1蛋白的制备方法及其应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US224A (en) 1837-06-03 Improvement in cotton-presses
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308483D0 (en) 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4963495A (en) 1984-10-05 1990-10-16 Genentech, Inc. Secretion of heterologous proteins
ATE78515T1 (de) 1984-10-05 1992-08-15 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5427780A (en) 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
AU622891B2 (en) 1985-10-30 1992-04-30 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4753794A (en) 1986-06-24 1988-06-28 The General Hospital Corporation Use of mullerian inhibiting substance as a contraceptive agent
US5010055A (en) 1986-06-24 1991-04-23 The General Hospital Corporation Use of EGF to reverse the contraceptive activity of MIS
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
GB8723662D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5061641A (en) 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
IL90190A0 (en) 1988-05-09 1989-12-15 Us Health Vector for secretion of proteins directly into periplasm or culture medium and method for synthesizing pure proteins utilizing the same
JPH02117384A (ja) * 1988-10-26 1990-05-01 Tonen Corp 酵母宿主によるヒト血清アルブミンａの製造
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
US5661126A (en) 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5641671A (en) 1990-07-06 1997-06-24 Unilever Patent Holdings B.V. Production of active Pseudomonas glumae lipase in homologous or heterologous hosts
WO1992013951A1 (en) 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
AU667578B2 (en) 1992-08-27 1996-03-28 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
CN1099868C (zh) 1993-11-16 2003-01-29 斯卡法玛公司 具有控制释放活性成分作用的囊
US5665557A (en) 1994-11-14 1997-09-09 Systemix, Inc. Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
US6495357B1 (en) 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2234931C (en) 1995-10-16 2010-01-19 Dana-Farber Cancer Institute Novel expression vectors and methods of use
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ATE314097T1 (de) 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6361989B1 (en) 1997-10-13 2002-03-26 Novozymes A/S α-amylase and α-amylase variants
US6156552A (en) 1998-02-18 2000-12-05 Novo Nordisk A/S Lipase variants
US6428978B1 (en) * 1998-05-08 2002-08-06 Cohesion Technologies, Inc. Methods for the production of gelatin and full-length triple helical collagen in recombinant cells
US6323007B1 (en) 1998-09-18 2001-11-27 Novozymes A/S 2,6-β-D-fructan hydrolase enzyme and processes for using the enzyme
ATE415469T1 (de) 1998-10-28 2008-12-15 Genentech Inc Verfahren zur gewinnung von heterologen polypeptiden aus bakterienzellen
JP4732591B2 (ja) 1999-03-29 2011-07-27 ノボザイムス アクティーゼルスカブ 分枝酵素活性を有するポリペプチド及びそれをコードする核酸
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
US6558939B1 (en) 1999-08-31 2003-05-06 Novozymes, A/S Proteases and variants thereof
CA2384991A1 (en) * 1999-09-14 2001-03-22 The General Hospital Corporation Use of mullerian inhibiting substance for treating excess androgen states
US6673352B1 (en) 1999-09-14 2004-01-06 The General Hospital Corporation Use of Mullerian inhibiting substance for treating excess androgen states
DE19944870A1 (de) 1999-09-18 2001-03-29 Aventis Pharma Gmbh Signalsequenzen zur Herstellung von Leu-Hirudin über Sekretion durch E. coli in das Kulturmedium
US6617143B1 (en) 1999-10-20 2003-09-09 Novozymes A/S Polypeptides having glucanotransferase activity and nucleic acids encoding same
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US6509181B1 (en) 2000-04-14 2003-01-21 Novozymes, A/S Polypeptides having haloperoxide activity
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
DE60237211D1 (de) 2001-08-20 2010-09-16 Gen Hospital Corp Spiegel der müllerschen inhibierenden substanz und ovarialreaktion
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP4809227B2 (ja) * 2003-09-26 2011-11-09 メルク セローノ ソシエテ アノニム タンパク質の産生に使用するためのリーダー配列
CA2599723A1 (en) 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
US20060216294A1 (en) 2005-03-24 2006-09-28 Mclennan Ian S Method of modulation
EP1951277A2 (en) 2005-10-14 2008-08-06 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
JP2009515832A (ja) 2005-10-26 2009-04-16 オタゴ イノベーション リミテッド 神経変性疾患の治療のためのミュラー管抑制物質（ｍｉｓ）受容体のモジュレーション方法
CN102517280A (zh) 2007-01-31 2012-06-27 菲尼克斯股份有限公司 用于提高表达的细菌前导序列
WO2008116161A2 (en) 2007-03-22 2008-09-25 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
WO2009012357A2 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
CA2699916A1 (en) 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US20120225824A1 (en) 2008-08-05 2012-09-06 The Trustees Of Columbia University In The City Of New York Mullerian inhibiting substance (mis) analogues
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
FR2993926A1 (fr) 2012-07-24 2014-01-31 Vianney Rabhi Turbomoteur basse-pression a combustion interne et/ou externe
HK1222331A1 (zh) 2013-03-12 2017-06-30 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用於疾病治疗的用途
US10258668B2 (en) 2013-09-20 2019-04-16 The General Hospital Corporation Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
EP4008339A1 (en) 2013-12-11 2022-06-08 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception
CA3212779A1 (en) 2021-03-22 2022-09-29 Patricia K. Donahoe Compositions and methods for preventing or delaying puberty in prepubescent non-human animals and humans

Also Published As

Publication number Publication date
JP2022180637A (ja) 2022-12-06
CA2904978A1 (en) 2014-10-09
DK2968470T3 (da) 2021-02-01
EP2968470B1 (en) 2020-10-28
JP6698015B2 (ja) 2020-05-27
AU2014248768A1 (en) 2015-09-24
US20160039898A1 (en) 2016-02-11
WO2014164981A1 (en) 2014-10-09
PL2968470T3 (pl) 2021-05-31
JP2020074789A (ja) 2020-05-21
JP2016518325A (ja) 2016-06-23
CN105473154A (zh) 2016-04-06
MX2015011846A (es) 2016-09-27
BR112015022181A8 (pt) 2018-01-23
KR20160029731A (ko) 2016-03-15
US11084860B2 (en) 2021-08-10
JP7597511B2 (ja) 2024-12-10
EP2968470A4 (en) 2016-10-12
BR112015022181A2 (pt) 2017-11-21
EP2968470A1 (en) 2016-01-20
HK1222331A1 (zh) 2017-06-30
US20220041677A1 (en) 2022-02-10
JP2024178382A (ja) 2024-12-24
US12497437B2 (en) 2025-12-16

Similar Documents

Publication Publication Date Title
ES2853935T3 (es) Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
US20240277812A1 (en) Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
US10258668B2 (en) Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
BRPI0616093A2 (pt) uso de inibidor de tecido de metaloproteinases (timp) ligado a fixações de glicosilfosfatidilinositol (gpi) para tratamento de lesões na pele
WO2018112168A1 (en) Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
ES2713068T3 (es) Derivados de IGFBP-3 y usos de los mismos
JP2016513645A (ja) 肥満の処置および体重の制御のための化合物および方法
HK40076899A (en) Use of mullerian inhibiting substance (mis) proteins for contraception
US20040242476A1 (en) Male contraceptives
ES2252032T3 (es) Modulacion de angiogenesis usando angiotensina-7 antiangiogenica y polinucleotidos codificantes para dicha sustancia para el tratamiento de tumores.
WO2025128821A1 (en) Compositions and methods for adp-ribosylation factor molecular trafficking
Rajaramen Effect of insulin-like growth factor binding protein-4 gene therapy on adenocarcinoma of the colon